Verastem Oncology Gears Up for Potential 2025 Launch of Avutometinib Plus Defactinib in KRAS Mutant LGSOC
• Verastem Oncology anticipates a potential FDA decision on avutometinib plus defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) by June 30, 2025.
• The company plans for a mid-2025 U.S. commercial launch of the combination therapy in recurrent KRAS mutant LGSOC, pending FDA approval.
• Clinical trials for avutometinib plus defactinib in metastatic pancreatic cancer and non-small cell lung cancer are progressing, with data updates expected in 2025.
• Verastem is set to file an IND for VS-7375, a KRAS G12D inhibitor, in Q1 2025 and initiate a Phase 1/2a trial in the U.S. by mid-2025.
© Copyright 2025. All Rights Reserved by MedPath